Tag: webinar

Clinical Research: Phase 1 - Phase 4

Novel Trial Approaches for Rare Cancer Patients, Upcoming Webinar

TORONTO (PRWEB) AUGUST 4, 2020 Join Rupa Doshi, Ph.D., Executive Director –Program Strategy, Oncology, Premier Research and Sameena Sharif, Ph.D., Senior Vice President, Product Strategy, Premier Research in a live webinar on Monday, August 24, 2020 at 11am EDT (4pm BST/UK). Rare cancers account for 22 percent of cancer diagnoses worldwide, yet there is no...

Patient and Stakeholder Engagement

The Art and Science of Selecting Patients for Phase 1 Oncology Studies

The primary purpose of early-stage clinical trials is to determine the recommended dose and toxicity profile of an investigational drug or multi-drug combination therapy. Since molecularly targeted agents (MTAs) and immunotherapies have toxicities that are distinct from cytotoxic chemotherapies, traditional dose escalation methods using toxicity-based endpoints may not be suitable for phase I studies of...

Consulting

Planning a Gene Therapy Trial? Ask an Expert — and Pay Attention

It’s been 46 years since researchers Theodore Friedmann and Richard Roblin published a landmark paper in the journal Science that posed a provocative question: “Gene therapy for human genetic disease?” And while clinical trials for gene therapy drugs have become much more common in the past 20 years — more than 2,400 had been conducted...

Clinical Research: Phase 1 - Phase 4

Gene Therapy 101: From the 1960s to Today

Gene therapy is a hot topic in clinical research today — and for good reason! These technologies have the potential to treat — and in some cases even cure — a wide range of conditions, including rare genetic disorders that previously had no effective therapies. What Is Gene Therapy? Gene therapies are a diverse group of...

The Outlook for Orphan Drug Research: A Live Webinar

DURHAM, N.C., DECEMBER 5, 2017 — The outlook for orphan drug research is more promising than ever, with regulators providing a progressive development platform and government reforms putting new emphasis on the need to treat rare diseases. Premier Research will examine the outlook for biotech and pharma companies at a live webinar on Tuesday, December...

Clinical Research: Phase 1 - Phase 4

A Vast Unmet Need: Challenges In Alzheimer’s Clinical Trials

Dementia is a growing global epidemic, affecting nearly 47 million people worldwide. That number is expected to approach 75 million by 2030, when the cost of patient care is forecast to reach $2 trillion. And the trend will only accelerate: By 2050, it’s estimated that 115 million will suffer from some form of dementia. Alzheimer’s...

Consulting

Webinar Explores Expanding Role of Immuno-Oncology Drugs

DURHAM, N.C., MAY 23, 2017 — Interleukin-2, interferon, and other immune-modulating agents have long been used to treat some solid malignancies, but their efficacy is generally limited to immunogenic cancers such as melanoma and kidney cancer. Until now. Today, multiple immuno-oncology pathways are under development, and we’ll explore this promising trend in a webinar on...

Consulting

Success in Neurodegenerative Disease Trials: Attend Our Nov. 15 Webinar

DURHAM, N.C., November 10, 2016 — Researchers developing treatments for neurodegenerative disorders face some of the biggest hurdles in planning and conducting clinical drug trials. Get advice on navigating this difficult terrain by attending a Premier Research webinar on Tuesday, November 15. Neurodegenerative Disease Research: Steps to a Successful Clinical Trial will describe a complex...

Quality

The Trends Reshaping Medical Device Trials: Attend Our Webinar on Nov. 2

DURHAM, N.C., OCTOBER 27, 2016 — Medical device and diagnostic companies are conducting more clinical trials than ever, a trend that’s giving rise to new procedures and best practices for studies that differ in many ways from pharmaceutical trials. Register for this webinar focused on the evolution of device clinical research on Wednesday, November 2....

Patient and Stakeholder Engagement

Register Now: Patient Advocacy Groups and Their Role in Orphan Drug Development

There are more than 7,000 known rare diseases, and these conditions afflict an estimated 30 million Americans (almost one in 10). Worldwide, some 350 million are living with a rare disease. But for 95 percent of these conditions, there are no FDA-approved treatments — not one. Conventional wisdom holds that innovation follows need: that if...